Identification of Biomarkers for Early Diagnosis of Acute Myocardial Infarction

Abstract

Acute myocardial infarction (AMI) is a common disease with serious consequences in mortality and cost. Here we aim to screen the differentially expressed genes (DEGs) as biomarkers for early diagnosis of AMI. The microarray data of AMI was downloaded from Gene Expression Omnibus (GEO), including two independent types of research GSE66360 and GSE62646. The DEGs between control and processed samples were screened out by using limma package. Meanwhile, we performed functional analysis of GO terms and/or KEGG pathways to observe the enriched pathways of the DEGs. Finally, regression analysis of raw data was performed by using packet affyPLM in R language. Dataset GSE62646 contained 53 DEGs (FC log2>1 and P value <0.05) between first-day samples from 28 STEMI patients and control samples from 14 patients without myocardial infarction history. There were 12 up-regulated and 41 down-regulated genes, 35 DEGs annotated. In GSE66360, a total of 3034 DEGs between 32 AMI patients and 38 healthy persons were obtained, including 1861 up-regulated and 1173 downregulated DEGs. The comparison of the DEGs in two datasets revealed four common up-regulated genes (EGR1, STAB1, SOCS3, TMEM176A). In enrichment analysis, STAB1, SOCS3, EGR1 involved in metabolic regulation and signaling pathways related to coronary artery disease with a characteristic change (P < 0.05). The DEGs, especially the four up-regulated common genes, could serve as biomarkers for early diagnosis of AMI. Additionally, the relative biological pathways these DEGs enriched in might provide a good reference to explore the molecular expression mechanism of AMI. J. Cell. Biochem. 119: 650-658, 2018. © 2017 Wiley Periodicals, Inc. KEY WORDS: ACUTE MYOCARDIAL INFARCTION; DIFFERENTIALLY EXPRESSED GENES; FUNCTIONAL ANNOTATION; BIOMARKERSA cute myocardial infarction (AMI) can cause heart failure, an irregular heartbeat, cardiogenic shock, or cardiac arrest [Risk et al., 2017]. It is the major cause of morbidity and mortality in the general population. This well-known heart attack is generally classified into ST-elevation MI (STEMI) and non-ST elevation MI (NSTEMI) [Moe and Wong, 2010]. According to the World Health Organization (WHO), annually, more than 3 million people are estimated with acute STEMI and that and more than 4 million suffers from NSTEMI [Organization, 2005;Reed et al., 2017]. In the modern society, the aging of population and comorbidities (e.g., obesity and metabolic syndrome) become more prevalent. All theses public health burden are the high risks of AMI. Besides, other health problems caused by ischemic heart disease are likely to increase even further [Yasuda and Shimokawa, 2009].The main treatments for STEMI include thrombolysis and percutaneous coronary intervention [Bates and Menees, 2012]. Hereinto, the percutaneous coronary intervention (PCI) should be performed within 90-120 min, if not, thrombolysis, preferably within 30 min of arrival to the hospital, is recommended [Bassand et al., 2005]. All these treatments need is extremely a time ...

LncRNA SNHG8 is identified as a key regulator of acute myocardial infarction by RNA-seq analysis

“…According to database prediction, miR-411-5p may be a target that binds to SOCS3 and ICAM1. These two genes have been confirmed to be associated with myocardial infarction [41,42].…”

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

“…Studies in the past few decades have identified biomarkers that have the potential to revolutionize medical science in terms of diagnosis, prognosis, and therapy (Chowdhury et al, 2013; Selleck et al, 2017; Cesano and Warren, 2018). Biomarkers have been identified for various diseases and disorders; for example, metabolic disorders (Boenzi and Diodato, 2018), cardiovascular disease (Ho et al, 2018), myocardial infarctions (Ge et al, 2018), gynecological diseases (Flores et al, 2018; Liu et al, 2018), neurological disorders (Lashley et al, 2018) and hepatic diseases (Wallace et al, 2016; Raghu et al, 2018). In the present era of high cancer prevalence, sensitive neoplastic biomarkers are a significant research focus, which could aid the early detection and prognosis of neoplastic changes (Tainsky, 2009; Admoni-Elisha et al, 2016; Andersen et al, 2017; Liu et al, 2018).…”

Comprehensive analyses of DNA methylation and gene expression profiles of Kawasaki disease

“…Then, the DMSs were mapped to genes, that is, differentially methylated genes (DMGs), according to the platform annotation file. The differentially expressed genes (DEGs) were identified through Limma package in R Bioconductor, with |log2 (fold change)| > 1 and P < 0.05 indicating significance . Since methylation may negatively influence gene expression, we performed a cross‐analysis of DMGs and DEGs.…”